Immunogenicity concerns for biosimilars so far don’t go beyond originator biologics But there are few data available on the impact of antidrug antibodies to biosimilars across rheumatic diseases and on switching. Early ankylosing spondylitis treatment stops transition from inflammatory to bone-forming fatty lesions “The earlier we treat intensively, the better impact you have on structural outcomes,” according to Dirk Elewaut, MD, PhD.
